High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
With an annual dividend yield of 3.06%, Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best Blue Chip Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. On May 7, Citi analyst […]
Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY). After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of fundamentals. Here is where I land on the $1,000 debate. The 24/7 Wall St. Price Target for Eli Lilly Eli Lilly trades at $948.45 as ... Eli Lilly Price Prediction: This Is Where The Stock Will End This Year
MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.
Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data for INBRX-106 plus KEYTRUDA in head and neck cancer, with plans to move into Phase 3. These updates signal further external partnerships around KEYTRUDA combinations, adding to Merck's oncology pipeline as key patents approach expiry. For investors watching large pharma, Merck's focus on...
UNH, MRK and QCOM drew focus as analysts highlighted growth drivers, pipeline strength and expanding AI and automotive opportunities.
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen. On April 30, Reuters reported that Merck & Co., Inc. (NYSE:MRK) surpassed first-quarter forecasts, with revenue of $16.3 billion, up 5% and beyond analysts’ $15.8 billion projection as per LSEG data. Keytruda sales went […]
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the
Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and dee
Inhibrx Biosciences releases positive preliminary results from its trial of a new head and neck cancer treatment.
Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.
Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best performing healthcare stocks so far in 2026. On April 30, Mizuho reaffirmed an Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN), setting a price target of $45. The rating update came after Merck noted during its fiscal Q1 earnings call that it believes Terns’ TERN-701 major molecular […]
The average American household spends about $519 a month on groceries, based on the latest BLS Consumer Expenditure Survey figure of $6,224 a year, and grocery prices are still rising: food-at-home prices were up 1.9% year over year as of March 2026. Add about $280 for utilities and roughly $100 for phone and internet, plus ... A $185,000 Portfolio That Covers Your Groceries, Utilities, and Phone Bill Every Month
Merck (NYSE:MRK) reported progress on its investigational oral PCSK9 inhibitor, enlicitide decanoate, including a biocatalytic large-scale manufacturing method. The company highlighted this new synthesis platform as a potential template for more sustainable macrocyclic peptide production. Separately, Merck faces an upcoming high profile trial concerning the safety of Gardasil, its widely used HPV vaccine. For investors watching NYSE:MRK, these updates sit alongside a stock that is priced at...
The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.
Merck heads toward a July 27 Gardasil trial while defending the HPV vaccine's safety record.
Moby summary of Codexis, Inc.'s Q1 2026 earnings call
An $83,400 annual paycheck sits comfortably above the U.S. median household income of roughly $80,610. Replacing that income with a portfolio, no employer required, is the question this article answers. The basic formula is income target divided by yield equals capital required. The more important issue is what changes across three yield tiers, and why ... A $1.5 Million Portfolio That Quietly Pays You $83,400 a Year, No Job Required
Over the last 7 days, the United States market has risen 3.2%, contributing to a 31% increase over the past year, with earnings expected to grow by 16% per annum in the coming years. In this thriving environment, identifying stocks that are trading below their estimated intrinsic value can be an effective strategy for investors looking to capitalize on potential growth opportunities.
Elizabeth Schwartz will head up government relations at the for-profit hospital trade association as health systems brace for federal funding cuts.
Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million
Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both entered 2026 with fresh distributions and updated holdings. The two funds chase dividends through very different rule sets, and the gap between them is wider than the surface suggests. Quality Screen vs. Yield ... Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain
Mounjaro generated $8.66 billion in sales in the first quarter.
Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.
Merck Animal Health selects Salesforce's Agentforce Life Sciences to support unified omnichannel engagement for veterinarians and animal health providers. New integrations from eGain and Mili extend Salesforce's AI capabilities into Service Cloud and private client workflows. These customer wins and ecosystem additions highlight further adoption of Salesforce's AI platform beyond prior product announcements. For investors watching Salesforce (NYSE:CRM), the focus has shifted from product...
With an upside potential of 21.26% as of May 3, Merck & Co., Inc. (NYSE:MRK) is included among the 10 Best Fortune 500 Stocks to Buy According to Analysts. Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. […]
EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
